Azacitidine

Azacitidine 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Recurrent Acute Myeloid Leukemia、Refractory Acute Myeloid Leukemia、Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome、Recurrent Secondary Acute Myeloid Leukemia。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Azacitidine 研究

• Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

  II 期招募中美国NCT05442216

• A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  I 期招募中美国NCT05735184

• Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

  I 期招募中美国NCT06429449

• A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

  I 期招募中中国NCT04275518

• Pacritinib in CMML

  I 期 / II 期招募中美国NCT06159491

• Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

  不适用招募中中国NCT06386302

• A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

  I 期招募中美国NCT06397027

• A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML

  I 期 / II 期招募中中国NCT05133882

• A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

  I 期招募中美国NCT05834244

• A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

  I 期 / II 期招募中美国NCT07389239

• A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

  II 期招募中美国NCT05365035

• Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse

  I 期 / II 期招募中中国NCT05270200

• A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

  II 期招募中美国NCT06561074

• Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

  I 期招募中美国NCT04245397

• Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT

  II 期 / III 期招募中中国NCT03793517

• Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

  II 期招募中中国NCT06316960

• Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML

  I 期 / II 期招募中中国NCT06757855

• Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS

  I 期招募中美国西班牙NCT06533761

• A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS

  II 期招募中瑞典NCT05788679

• Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

  I 期 / II 期招募中美国NCT03661307

• Venetoclax Basket Trial for High Risk Hematologic Malignancies

  I 期招募中美国NCT05292664

• A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients

  II 期招募中中国NCT06928376

• A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma

  I 期 / II 期招募中中国NCT06683885

• Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

  II 期招募中美国NCT03418038

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。